ANIK trades 44.3% below Wall Street's consensus target of $21.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ANIK achieves its forward estimates and maintains a stable P/E multiple of 13.9x. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Anika Therapeutics, Inc. (ANIK) has a Wall Street consensus price target of $21.00, based on estimates from 7 covering analysts. With the stock currently trading at $14.55, this represents a potential upside of +44.3%. The company has a market capitalization of $195M.
Analyst price targets range from a low of $21.00 to a high of $21.00, representing a 0% spread in expectations. The median target of $21.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, ANIK trades at a trailing P/E of -110.3x and forward P/E of 13.9x. Analysts expect EPS to grow +472.6% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 MDXGMiMedx Group, Inc. | $482M | $3.31 | $7.50 | +126.6% | Buy | — | 15 |
 NVCRNovocure Ltd | $1.5B | $13.28 | $26.00 | +95.8% | Buy | — | 15 |
 OSUROraSure Technologies, Inc. | $237M | $3.44 | $7.00 | +103.5% | Hold | — | 13 |
 ATRCAtriCure, Inc. | $3.0B | $58.54 | $60.17 | +2.8% | Buy | 541.5x | 20 |
 LNTHLantheus Holdings, Inc. | $6.6B | $100.61 | $102.65 | +2.0% | Buy | 18.8x | 19 |
 HALOHalozyme Therapeutics, Inc. | $12.3B | $103.63 | $110.00 | +6.1% | Buy | 12.0x | 27 |
 ALGNAlign Technology, Inc. | $11.9B | $166.00 | $190.00 | +14.5% | Buy | 14.9x | 33 |
 GMEDGlobus Medical, Inc. | $9.6B | $71.05 | $93.13 | +31.1% | Buy | 14.2x | 37 |
 PRGOPerrigo Company plc | $2.2B | $15.85 | $36.20 | +128.4% | Hold | 6.9x | 36 |
 OFIXOrthofix Medical Inc. | $318M | $7.87 | $13.40 | +70.3% | Hold | — | 17 |
Quick answers to the most common questions about buying ANIK stock.
The consensus Wall Street price target for ANIK is $21, representing 44.3% upside from the current price of $14.55. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ANIK has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $21 implies 44.3% upside from current levels.
With a forward P/E of 13.8571x, ANIK trades at a relatively low valuation. The consensus target of $21 implies 44.3% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $21 for ANIK, while the most conservative target is $21. The consensus of $21 represents the median expectation. These targets typically reflect 12-month expectations.
ANIK is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ANIK stock forecast based on 7 Wall Street analysts shows a consensus price target of $21, with estimates ranging from $21 (bear case) to $21 (bull case). The median consensus rating is "Buy".
ANIK trades at a forward P/E ratio of 13.9x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on ANIK, with a "Buy" consensus rating and $21 price target (44.3% upside). 4 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ANIK analyst price targets range from $21 to $21, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $21 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.